| Dynamic I maging of I ndividual R emyelination P rofiles in M ultiple S clerosis B Bodini, M Veronese, D García‐Lorenzo, M Battaglini, E Poirion, ... Annals of neurology 79 (5), 726-738, 2016 | 230 | 2016 |
| Imaging central nervous system myelin by positron emission tomography in multiple sclerosis using [methyl‐11C]‐2‐(4′‐methylaminophenyl)‐ 6 … B Stankoff, L Freeman, MS Aigrot, A Chardain, F Dollé, A Williams, ... Annals of neurology 69 (4), 673-680, 2011 | 219 | 2011 |
| Brain networks disconnection in early multiple sclerosis cognitive deficits: an anatomofunctional study C Louapre, V Perlbarg, D García‐Lorenzo, M Urbanski, H Benali, ... Human brain mapping 35 (9), 4706-4717, 2014 | 146 | 2014 |
| Imaging outcome measures of neuroprotection and repair in MS: a consensus statement from NAIMS J Oh, D Ontaneda, C Azevedo, EC Klawiter, M Absinta, DL Arnold, ... Neurology 92 (11), 519-533, 2019 | 65 | 2019 |
| Expanding the spectrum of genes involved in Huntington disease using a combined clinical and genetic approach LL Mariani, C Tesson, P Charles, C Cazeneuve, V Hahn, K Youssov, ... JAMA neurology 73 (9), 1105-1114, 2016 | 54 | 2016 |
| The neuronal component of gray matter damage in multiple sclerosis: A [11C]flumazenil positron emission tomography study L Freeman, D Garcia‐Lorenzo, L Bottin, C Leroy, C Louapre, B Bodini, ... Annals of neurology 78 (4), 554-567, 2015 | 49 | 2015 |
| High-efficacy therapies for treatment-naïve individuals with relapsing–remitting multiple sclerosis L Freeman, EE Longbrake, PK Coyle, B Hendin, T Vollmer CNS drugs 36 (12), 1285-1299, 2022 | 44 | 2022 |
| Enrollment of non-white participants and reporting of race and ethnicity in phase III trials of multiple sclerosis DMTs: a systematic review HM Onuorah, O Charron, E Meltzer, A Montague, A Crispino, A Largent, ... Neurology 98 (9), e880-e892, 2022 | 38 | 2022 |
| Imaging markers of multiple sclerosis prognosis C Louapre, B Bodini, C Lubetzki, L Freeman, B Stankoff Current Opinion in Neurology 30 (3), 231-236, 2017 | 36 | 2017 |
| Disease modifying therapies continue to drive up health care cost among individuals with multiple sclerosis Y Kim, TM Krause, P Blum, L Freeman Multiple sclerosis and related disorders 30, 69-75, 2019 | 34 | 2019 |
| Quantitative assessment of the evolution of cerebellar signs in spinocerebellar ataxias E Chan, P Charles, P Ribai, C Goizet, C Marelli, CM Vincitorio, AL Bayon, ... Movement Disorders 26 (3), 534-538, 2011 | 32 | 2011 |
| Microglia activation in basal ganglia is a late event in Huntington disease pathophysiology NP Rocha, O Charron, LB Latham, GD Colpo, P Zanotti-Fregonara, M Yu, ... Neurology: Neuroimmunology & Neuroinflammation 8 (3), e984, 2021 | 31 | 2021 |
| Effect of intrinsic and extrinsic factors on global and regional cortical thickness KA Govindarajan, L Freeman, C Cai, MH Rahbar, PA Narayana PLoS One 9 (5), e96429, 2014 | 25 | 2014 |
| Central vein sign: A diagnostic biomarker in multiple sclerosis (CAVS-MS) study protocol for a prospective multicenter trial D Ontaneda, P Sati, P Raza, M Kilbane, E Gombos, E Alvarez, C Azevedo, ... NeuroImage: Clinical 32, 102834, 2021 | 24 | 2021 |
| Exploring the relationship between Endothelin-1 and peripheral inflammation in multiple sclerosis NP Rocha, GD Colpo, J Bravo-Alegria, JA Lincoln, JS Wolinsky, ... Journal of Neuroimmunology 326, 45-48, 2019 | 18 | 2019 |
| Dense module searching for gene networks associated with multiple sclerosis AM Manuel, Y Dai, LA Freeman, P Jia, Z Zhao BMC Medical Genomics 13, 1-12, 2020 | 15 | 2020 |
| Expanded neurochemical profile in the early stage of Huntington disease using proton magnetic resonance spectroscopy IM Adanyeguh, ML Monin, D Rinaldi, L Freeman, A Durr, S Lehéricy, ... NMR in Biomedicine 31 (3), e3880, 2018 | 14 | 2018 |
| Retrospective claims analysis of treatment patterns, relapse, utilization, and cost among patients with multiple sclerosis initiating second-line disease-modifying therapy L Freeman, A Kee, M Tian, R Mehta Drugs-Real World Outcomes 8 (4), 497-508, 2021 | 12 | 2021 |
| Variant or sporadic Creutzfeldt-Jakob disease? JP Brandel, D Galanaud, L Freeman, JL Laplanche, S Haik The Lancet 375 (9718), 889, 2010 | 11 | 2010 |
| An integrative study of genetic variants with brain tissue expression identifies viral etiology and potential drug targets of multiple sclerosis AM Manuel, Y Dai, LA Freeman, P Jia, Z Zhao Molecular and Cellular Neuroscience 115, 103656, 2021 | 10 | 2021 |
